Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Anti-IL-17RA monoclonal antibody

Brodalumab

Brand names: Kyntheum

Brodalumab is a human monoclonal antibody used for moderate-to-severe plaque psoriasis in adults who have not responded adequately to other systemic therapies.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds the interleukin-17 receptor A subunit, blocking signalling of several IL-17 cytokines and thereby reducing the inflammation that drives psoriatic plaques.

Prescribing in practice

  • Suicidal ideation and behaviour, including completed suicide, have been reported; assess psychiatric history and advise patients and carers to report new or worsening mood symptoms, and discontinue if such symptoms emerge.
  • Screen for tuberculosis and active infection before starting, and avoid in patients with active Crohn's disease as IL-17 inhibition can exacerbate inflammatory bowel disease.
  • Live vaccines should be avoided during treatment.

Monitoring

Monitor for signs of infection and for new or worsening depression, mood changes or suicidal ideation throughout treatment.

Counselling the patient

  • This is a self-injected treatment; you will be taught the correct technique.
  • Seek urgent help if you experience new or worsening low mood or thoughts of self-harm.
  • Tell your clinician promptly about any signs of infection.

Evidence & guidelines

Brodalumab is recommended by NICE as an option for moderate-to-severe plaque psoriasis under its usual biologic eligibility criteria.

Reference: NICE TA511; BAD biologics guideline; MHRA; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways